Device Cardiology

Sherpapak

Payments companies reported to CMS as associated with Sherpapak. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$62Kassociated payments (2023-2025)
296clinicians with associated payments
1company reporting

By year

2024 $54K
2025 $7,571

Payments reported as associated with Sherpapak, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Thoracic Surgery (Cardiothoracic Vascular Surgery) $19K
Advanced Heart Failure and Transplant Cardiology $11K
Transplant Surgery $8,852
Pulmonary Disease $6,165
Surgery $4,052
Cardiovascular Disease $1,951

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Sherpapak

These are the largest totals companies reported as associated with Sherpapak. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Jeffrey Teuteberg Stanford, CA Advanced Heart Failure and Transplant Cardiology $2,248.75
Kiran Dhanireddy Tampa, FL Transplant Surgery $1,509.59
Jon Kobashigawa Los Angeles, CA Advanced Heart Failure and Transplant Cardiology $1,500.00
Rajat Walia Phoenix, AZ Pulmonary Disease $1,227.86
Maziar Khorsandi Columbus, OH Thoracic Surgery (Cardiothoracic Vascular Surgery) $777.54
Reinaldo Rampolla West Hollywood, CA Pulmonary Disease $717.64
Henry Randall Kansas City, MO Transplant Surgery $678.86
Stephanie Chang New York, NY Thoracic Surgery (Cardiothoracic Vascular Surgery) $637.17
Michael Smith Phoenix, AZ Thoracic Surgery (Cardiothoracic Vascular Surgery) $614.78
Lara Schaheen Phoenix, AZ Thoracic Surgery (Cardiothoracic Vascular Surgery) $614.78

Prescribed Sherpapak?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.